 EMERYVILLE, Calif., Aug. 14, 2020 GLOBE NEWSWIRE -- Adamas Pharmaceuticals, Inc. Nasdaq: ADMS today announced that the compensation committee of the companys board of directors granted three new employees the option to purchase an aggregate of 36,000 shares of the companys common stock, at a per share exercise price of 3.78, the closing trading price on August 7, and restricted stock units to acquire 18,000 shares of the companys common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the companys board of directors in March 2016 under Rule 5653c4 of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company. About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI amantadine extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit Peter Vozzo Westwicke Partners 443-213-0505 Sarah Mathieson Vice President, Communications Engagement 510-450-3528 